Propionic acid and not caproic acid, attenuates nonalcoholic steatohepatitis and improves (cerebro) vascular functions in obese Ldlr<sup>−/−</sup>.Leiden mice by Tengeler, Anouk C. et al.
The FASEB Journal. 2020;00:1–19.    | 1wileyonlinelibrary.com/journal/fsb2
Received: 27 February 2020 | Revised: 7 May 2020 | Accepted: 11 May 2020
DOI: 10.1096/fj.202000455R  
R E S E A R C H  A R T I C L E
Propionic acid and not caproic acid, attenuates nonalcoholic 
steatohepatitis and improves (cerebro) vascular functions in obese 
Ldlr−/−.Leiden mice
Anouk C. Tengeler1 |   Eveline Gart2,3 |   Maximilian Wiesmann1 |   Ilse A. C. Arnoldussen1 |  
Wim van Duyvenvoorde2 |   Marloes Hoogstad1 |   Pieter J. Dederen1 |   Vivienne Verweij1 |   
Bram Geenen1 |   Tamas Kozicz1,4 |   Robert Kleemann1,5 |   Martine C. Morrison2,3 |   
Amanda J. Kiliaan1
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology
Anouk C. Tengeler and Eveline Gart are share first authorship. 
Martine C. Morrison and Amanda J. Kiliaan are share last authorship.  
Abbreviations: ASL, arterial spin labeling; B2M, Β2-microglobulin; BOLD, blood oxygen level dependent; CA, caproic acid; CBF, cerebral blood flow; 
CE, cholesteryl ester; CLS, crown-like structures; COX, cytochrome c oxidase; CS, citrate synthase; DAB-Ni, diaminobenzidine-nickel; DCX, doublecortin; 
DTI, diffusion tensor imaging; DVC, digital ventilated cages; FA, fractional anisotropy; FAIR, flow-sensitive alternating inversion recovery; FAS, fatty acid 
synthase; FC, free cholesterol; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GLUT-1, glucose transporter 1; gWAT, gonadal white adipose tissue; 
HE, hematoxylin-eosin; HFD, high-fat diet; IBA-1, ionized calcium-binding adapter molecule 1; IHC, Immunohistochemistry; IPA, Ingenuity Pathway 
Analysis; Ldlr−/−, low-density lipoprotein receptor knockout; MD, mean diffusivity; mWAT, mesenteric white adipose tissue; MWM, morris water maze; 
NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NMDA, n-methyl-d-aspartate; PA, propionic acid; PSD-95, post-synaptic 
density-95; rs-fMRI, resting-state functional MRI; SAA, serum amyloid A; SBP, systolic blood pressure; SCC, succinate cytochrome c oxidoreductase; 
SCFA, short-chain fatty acid; sWAT, subcutaneous white adipose tissue; SYP1, synaptophysin; TG, triglyceride; WAT, white adipose tissue.
1Department of Anatomy, Donders 
Institute for Brain, Cognition and Behavior, 
Preclinical Imaging Centre, Radboud 
University Medical Center, Nijmegen, the 
Netherlands
2Department of Metabolic Health Research, 
The Netherlands Organisation for Applied 
Scientific Research (TNO), Leiden, the 
Netherlands
3Human and Animal Physiology, 
Wageningen University, Wageningen, the 
Netherlands
4Department of Biochemistry and 
Molecular Biology, Mayo Clinic, Rochester, 
MN, USA
5Department of Vascular Surgery, Leiden 
University Medical Center, Leiden, the 
Netherlands
Correspondence
Amanda J. Kiliaan, Department of 
Anatomy, Radboud University Medical 
Center, Donders Institute for Brain, 
Abstract
The obesity epidemic increases the interest to elucidate impact of short-chain fatty 
acids on metabolism, obesity, and the brain. We investigated the effects of propionic 
acid (PA) and caproic acid (CA) on metabolic risk factors, liver and adipose tissue 
pathology, brain function, structure (by MRI), and gene expression, during obesity 
development in Ldlr−/−.Leiden mice. Ldlr−/−.Leiden mice received 16 weeks either 
a high-fat diet (HFD) to induce obesity, or chow as reference group. Next, obese 
HFD-fed mice were treated 12 weeks with (a) HFD + CA (CA), (b) HFD + PA (PA), 
or (c) a HFD-control group. PA reduced the body weight and systolic blood pres-
sure, lowered fasting insulin levels, and reduced HFD-induced liver macrovesicular 
steatosis, hypertrophy, inflammation, and collagen content. PA increased the amount 
of glucose transporter type 1-positive cerebral blood vessels, reverted cerebral vaso-
reactivity, and HFD-induced effects in microstructural gray and white matter integ-
rity of optic tract, and somatosensory and visual cortex. PA and CA also reverted 
HFD-induced effects in functional connectivity between visual and auditory cortex. 
However, PA mice were more anxious in open field, and showed reduced activity of 
synaptogenesis and glutamate regulators in hippocampus. Therefore, PA treatment 
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1 |  INTRODUCTION
The prevalence of obesity has increased considerately 
worldwide over the past decades.1 Obesity is associated with 
ectopic fat accumulation, dyslipidemia, hyperinsulinemia, 
and it promotes the development of nonalcoholic fatty liver 
disease (NAFLD).2 NAFLD encompasses a spectrum of 
liver disease, ranging from simple steatosis to the more se-
vere stage of nonalcoholic steatohepatitis (NASH). NASH 
is characterized by steatosis and lobular inflammation,3,4 
and can progress to liver fibrosis.5 Other than modifying 
lifestyle factors, for instance weight loss through dietary 
advice and physical activity, no approved pharmacologi-
cal therapy is yet available for NASH. In addition to the 
dysfunction of peripheral metabolic organs, obesity is also 
associated with mitochondrial dysfunction and alterations 
in brain structure and cognitive dysfunction.6,7 Obesity-
associated changes in white matter have been reported in 
numerous studies8-10 and effects on the cerebrovasculature, 
that is, decreased cerebral vasoreactivity and glucose trans-
porter 1 (GLUT-1) expression, a marker for vascular endo-
thelium cells and vascular health.11,12
Short-chain fatty acids (SCFAs) have already shown 
some beneficial effects on obesity development. For ex-
ample, CA has been reported to have possible antilipo-
genic effects.13-16 Moreover, a small-scale clinical study 
showed that an elevation of colonic PA levels was asso-
ciated with reduced weight gain and reductions in liver 
lipids.17 In rodent studies, PA has been shown to protect 
against diet-induced obesity.18-21 Furthermore, elevated 
PA levels were associated with reduced visceral adiposity 
and steatohepatitis in obese mice that were treated with 
fructo-oligosaccharides.22
Herein, we investigated whether CA and PA can atten-
uate the development of HFD-induced obesity and associ-
ated NASH, liver fibrosis and associated brain dysfunction 
on functional and structural level. To do so, we used the 
low-density lipoprotein receptor knockout (Ldlr−/−).Leiden 
mice which develop dyslipidemia, hyperinsulinemia, obesity, 
NASH, liver fibrosis, and hypertension in conjunction with 
brain dysfunction in a period of about 30 weeks on HFD.6,23 
PA and CA were administered as dietary supplement in a 
therapeutic setting, that is, after a 16-week run-in to establish 
obesity.
2 |  MATERIALS AND METHODS
2.1 | Mice, diets, and study design
This was a randomized and blinded (blinded for investiga-
tors and outcome assessors) controlled study. Male Ldlr−/−.
Leiden mice were obtained from a specific pathogen-
free breeding stock at TNO Metabolic Health Research 
(Leiden, the Netherlands) and were housed in the Preclinical 
Imaging Center (PRIME) at the Animal Research Facility, 
Radboudumc Nijmegen, the Netherlands. Mice were group-
housed in digital ventilated cages (DVC; Tecniplast SPA, 
Buguggiate (VA) Italy) in which locomotor activity of the 
mice can be tracked 24 hours/day. Mice were housed in con-
ventional animal rooms (relative humidity 50%-60%, temper-
ature 21°C, light cycle 7 AM-7 PM), 2-3 mice per cage with 
ad libitum access to food and water. All animal experiments 
were carried out in accordance with international European 
ethical standards (European Directive 2010/63/EU) and were 
approved by the TNO Animal Welfare Body (Permit num-
ber: TNO-345) and the Veterinary Authority of the Radboud 
university medical center (Radboudumc; Permit number: 
RU-DECnon break ingsp ace2017-0063-002). All applicable 
(inter)national, and institutional guidelines for the care and 
use of animals were followed and are reported herein in ac-
cordance with the ARRIVE guidelines.24
The study design of this experiment is shown in Figure 1A. 
From weaning at 3 weeks of age onward, all groups received 
a standard chow diet (9.0% kcal fat, 58.0% carbohydrates, 
and 33.0% kcal protein Sniff R/M-H diet V1530, Sniff 
Spezialdiäten GmbH, Soest, Germany). At 15 weeks of age, 
mice were divided into 4 experimental groups (N = 15 per 
group) that were matched for body weight prior to treatment. 
Mice in group 1 were kept on the chow diet, and mice in 
group 2-4 were switched to an HFD (45.0% kcal fat, 35.0% 
carbohydrates and 20.0% kcal protein, D12451, Research 
Diets Inc, New Brunswick, USA) with anise. From 31 weeks 
of age until the end of the study (for a total of 12 weeks), 
group 3 HFD was supplemented with 2.5% w/w CA (CA 
mice), and group 4 with 2.5% w/w PA (PA mice).
Food intake at cage level and individual body weight 
were monitored weekly. Blood samples were collected be-
fore and after 8  weeks of treatment. Systolic blood pres-
sure, cognition with the Morris water maze test (MWM), 
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Netherlands.
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behavior in an Open Field Test and motor skills with the 
Rotarod experiment were assessed before treatment and 
after 9-10 weeks of treatment. Brain function and structure 
were measured using magnetic resonance imaging (MRI) 
after 11  weeks of treatment. After 12  weeks, mice were 
sacrificed via cervical dislocation followed by decapita-
tion. One HFD-mouse was sacrificed early in the study due 
to health concerns resulting from fighting, and was, there-
fore, excluded from all analyses.
2.2 | Plasma measurements
Blood samples were collected after 5 hours fast via tail vein 
bleeding to determine whole blood glucose, and for isolation 
of EDTA plasma in which total cholesterol, triglycerides, 
serum amyloid A (SAA), and insulin were determined as de-
scribed previously.23
2.3 | Systolic blood pressure
SBP was measured using a computerized and warmed 
tail-cuff plethysmography device (IITC Life Scientific 
Instruments, Woodland Hill, CA, USA). One trial, consisting 
of 10 measurements, was used to habituate the mice to the 
restrainer and acclimatize the animals to the complete proce-
dure. SBP was then measured for a total of 20 measurements, 
in two trials on two consecutive days and expressed as mean 
SBP in millimeter of mercury (mm Hg).
F I G U R E  1  Study design and body weight. A, Study design. From 15 to 30 weeks of age, Ldlr−/− mice received either a chow diet or an HFD 
diet. At 31 weeks of age CA and PA treatment started. Systolic blood pressure was measured, and plasma samples were collected (see droplet). 
Behavior and cognition were assessed, and MRI-experiments were performed. In week 43, all mice were sacrificed via cervical dislocation 
followed by decapitation. B, Body weight. An HFD supplemented with CA or PA started at 31 weeks of age. Reference mice were kept on chow. 
HFD: high-fat diet; PA: propionic acid; CA: caproic acid; OFT: Open Field test; MWM: Morris water maze. Data are presented as mean ± SEM. 
*P < .05; ***P < .001. N = 14 (HFD) or N = 15 (chow, CA, PA) mice per group
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2.4 | Liver histological and 
biochemical analyses
The liver was isolated and weighed. Development of NAFLD 
was analyzed in the medial liver lobe in 3 μm liver hematox-
ylin-eosin (HE) stained sections by a board-certified patholo-
gist using a well-established rodent NASH scoring method 
adapted from the human NAFLD activity score (NAS).23,25 
Briefly, the level of total steatosis or hypertrophy (abnormally 
enlarged hepatocytes) per mouse was expressed as a percent-
age of the total liver section affected. Hepatic inflammation 
was quantified by counting the number of inflammatory ag-
gregates in five fields per mouse at 100x magnification (field 
of view 4.15 mm2) and expressed as the number of foci per 
mm2.
The sinister lobe was snap-frozen in liquid nitrogen and 
stored at −80°C for biochemical analyses. Hepatic total col-
lagen content was determined with a hydroxyproline assay 
(Quickzyme, Leiden, the Netherlands) and protein with a 
total protein assay (Quickzyme) according to the manufactur-
er's instructions. The hepatic ketone body β-hydroxybutyrate 
was measured with a colorimetric assay kit (Cayman chem-
ical, Michigan, USA) and protein content was assayed with 
(Pierce BCA protein assay kit, Thermo Fisher Scientific, 
Waltham, USA) in an assay buffer containing protease in-
hibitors (100 mg/mL) following the manufacturer's protocol.
Liver lipids were determined in a 100  mg/mL phos-
phate-buffered saline homogenate following the Bligh and 
Dyer method,26 then separated by high-performance thin-
layer chromatography on silica gel plates. Subsequently, the 
lipids were stained as described previously,23 and analyzed 
with ChemiDoc Touch Imaging System (Bio-Rad, Hercules, 
USA). Liver triglyceride (TG), cholesterol ester (CE), and 
free cholesterol (FC) content was quantified using Image-lab 
version 5.2.1 software (Bio-Rad, Hercules, USA) and ex-
pressed per mg liver protein. In the same liver homogenates, 
the glycogen content was determined according to the man-
ufacturer's protocol (MAK016 Glycogen assay kit, Sigma-
Aldrich, Steinheim, Germany).
2.5 | White adipose tissue (WAT) analyses
Gonadal (gWAT), mesenteric (mWAT), and subcutaneous 
(sWAT) WAT depots were isolated, weighed, and 5  μm 
paraffin embedded sections were stained with hematoxylin-
phloxine-saffron and scanned for digital analysis (Aperio 
AT2, Leica Biosystems, Amsterdam, the Netherlands). Size 
of adipose cells were analyzed using Adiposoft27 an open-
source automated plug-in for the image processing package 
Fiji28 for ImageJ.29 Inflammation was quantified by counting 
the number of crown-like structures (CLS; the histological 
hallmark of adipose tissue inflammation30 in the same fields 
used for adipocyte size analysis and expressed as number of 
CLS per 1000 adipocytes.
2.6 | Digital ventilated cages (DVC)
Mice were housed in DVC cages (2-3 mice per cage) dur-
ing the experiment to study locomotor activity 24 hours/day. 
Activity was monitored via 12 electrodes underneath the 
home-cage, as described previously.31,32 For analysis of the 
processed results, we used activity data of 2 days and 2 nights 
before the start of the interventions, and 2 days and 2 nights 
at the end of the experiment. Activity measures were cor-
rected for the number of mice per cage.
2.7 | Rotarod
To study sensory-motor integration mice were placed on a 
rotating rod (3.18 cm in diameter; IITC Inc, Woodland Hills, 
CA, USA) and their ability to remain on the device was re-
corded as latency to fall. First, mice were accustomed to the 
task by placing them on a stationary rod for 1  minute fol-
lowed by a test trial at 10 rpm. Next, four accelerating trials 
with intervals of 30 minutes were performed (4 to 40 rpm) 
with a maximum duration of 300 seconds.
2.8 | Open field
Explorative behavior and locomotion were assessed in the 
open field test. Mice were placed individually in a square 
open field (45  cm  ×  45  cm  ×  30  cm) with transparent 
Plexiglas walls, and recorded for 10  minutes. Locomotion 
and explorative behavior were automatically calculated with 
EthoVision XT10.1 (Noldus, Wageningen, the Netherlands).
2.9 | Morris water maze
The MWM was used to examine long-term memory and spa-
tial learning abilities. During the acquisition phase, the mice 
were trained to find the platform in a circular pool (diameter 
108 cm) that was filled with water (21-22°C), made opaque 
by adding milk powder. The platform (diameter 8 cm) was 
submerged 1 cm below the water surface and located in the 
North-East quadrant of the pool. Mice performed 4 acqui-
sition trials per day starting from four different positions 
(South, North, East, West; maximal swimming time 120 s; 
30 s on the platform; inter-trial interval 60 min) during four 
consecutive days. Visual cues were present on the four walls 
surrounding the pool at a distance of 0.5 m. All trials were 
recorded and latency to find the platform (s) was used as a 
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measure for spatial learning. Mice performed a single probe 
trial at the end of day 4 of acquisition, in which the platform 
was removed from the pool.
During this probe trial, the mice were allowed to swim 
freely for 120  seconds. Trials were recorded and analyzed 
with EthoVision XT 10.1.
2.10 | Functional and structural brain 
experiments using MRI
All MRI measurements were performed using an 11.7-T 
BioSpec Avance III small animal MR system (Bruker 
BioSpin, Ettlingen, Germany). Isoflurane (Abbott Animal 
Health, Abbott Park, IL, USA) was used for anesthesia (3.5% 
for induction and ~1.7% for maintenance) in a 1:2 oxygen and 
air mixture). Imaging parameters can be found in Table S1.
Arterial spin labeling (ASL) was assessed to indicate 
cerebral blood flow (CBF) levels using an established ASL 
method with flow-sensitive alternating inversion recovery 
(FAIR) technique.33 To induce vasoconstriction, the normal 
1:2 oxygen-air mixture was changed to a 3:0 oxygen and 
air mixture. CBF values from both conditions were used to 
evaluate the ability of the cerebrovasculature to adapt from 
a normal condition to a vasoconstrictive condition, which is 
referred to as cerebral vasoreactivity.34 Cerebral vasoreactiv-
ity was calculated by subtraction of the vasoconstriction CBF 
from the normal CBF values, and this was then divided by the 
sum of the normal and vasoconstrictive CBF values. To cal-
culate regional CBF we used the same protocol as described 
previously.35 CBF was measured in the total brain, cortex, 
thalamus (an important brain structure for relaying motor sig-
nals to the cortex), and the hippocampus (an important brain 
structure for memory consolidation).
To investigate white and gray matter integrity in the brain, 
diffusion tensor imaging (DTI) was employed as described.36,37 
Fractional anisotropy is a marker of the degree of myelination 
and fiber density of white matter, while mean diffusivity char-
acterizes an inverse measure of the membrane density.38 These 
scalars were measured in several manually selected white matter 
and gray matter areas: fornix and corpus callosum, and regions 
in the left and right hemisphere: auditory cortex, hippocampus, 
motor cortex, optic tract, somatosensory cortex, visual cortex, 
caudate putamen, anterior commissure, amygdala, external cap-
sule, fimbria, forceps minor, and internal capsule.39
Resting-state functional MRI (rs-fMRI) acquisition was 
performed to assess functional connectivity between specific 
regions of interest (ROI) that support multiple cognitive and 
motor processes: dorsal hippocampus, ventral hippocampus, 
auditory cortex, motor cortex, somatosensory cortex, and 
visual cortex. Functional connectivity between ROIs was 
calculated from the blood oxygen level-dependent (BOLD) 
time series using total and partial correlation analyses as 
previously described.36 Partial correlations accentuates the 
direct connectivity between two ROI while it regresses the 
temporal BOLD signal from all other ROIs.36,40
2.11 | Enzymatic mitochondrial activity 
analysis in brain tissue
A homogenate of snap-frozen cerebellum (N = 8 randomly se-
lected animals per treatment group) was made with a glass-glass 
potter tube in SEF buffer (0.25  M sucrose, 2  mM  K-EDTA, 
10 mM phosphate buffer, pH 7.4) to obtain a 5% w/v homogen-
ate. The homogenized samples were centrifuged at 600 g for 
10 minutes at 2°C and the supernatant underwent three freeze-
thaw cycles to adequately permeabilize the mitochondria. 
Enzyme activities of the individual complexes of the respira-
tory chain (complex I, II, III and IV), citrate synthase (CS) and 
Succinate cytochrome C oxidoreductase (SCC) were measured 
spectrophotometrically on a KoneLab 20XT analyzer (Thermo 
Scientific, Waltham, MA, USA), following previously de-
scribed methods.41,42 Enzyme activities were normalized to CS 
activity (a marker for the number of mitochondria43).
2.12 | Quantitative real-time polymerase 
chain reaction
Snap-frozen hippocampi were used for mRNA level analy-
sis using quantitative real-time polymerase chain reaction 
(qRT-PCR) of post-synaptic density-95 (PSD-95) and synap-
tophysin (SYP-1), as previously described.44 Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and β2-microglobulin 
(B2M) were used as reference genes. To determine the 
threshold cycle (CT) values, the StepOne Software version 
2.2.2 was used. CT values were normalized against the aver-
age of the two reference genes and transformed to the com-
parative CT values using the Pfaffl method.45
2.13 | Gene expression analysis using the 
NanoString neuroinflammation panel
The isolated hippocampal RNA, as used previously for 
qRT-PCR, concentration was measured spectrophotometri-
cally using a NanoDrop 1000 (Isogen Life Science, De 
Meern, Netherlands). To assess the quality of the isolated 
RNA, the 2100 Bioanalyzer (Agilent Technologies, Amstelveen, 
Netherlands) was used. Molecular barcodes from the nCounter 
Neuroinflammation panel (XT-CSO-MNROI1-12) code set, 
included 770 genes and 13 internal reference genes for normal-
ization. The isolated RNA (25ng/ul sample) was used to make 
a reporter code set master mix and samples from chow, HFD 
and PA were incubated for 24 hours at 65°C for hybridization 
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following the manufacturer's protocol. Hybridized samples 
were then loaded on to an nCounter cartridge and run on the 
nCounter SPRINT (NanoString Technologies, Seattle, WA, 
USA) to measure barcode signals. nSolver 4.0 (NanoString 
Technologies, USA) was used to analyze the geometric mean 
of internal reference genes was used to compute the reference 
normalization factor. Internal references with a count below 
background levels or outside the 0.10-10.0 range normaliza-
tion factor were excluded. Herein internal reference Asb10 
average count fell below background levels and Xpnpep1 was 
affected by our treatment, and both had to be excluded from 
the analyses. Normalized gene expression data were used for 
gene enrichment analysis across pathways and biological pro-
cesses with the Ingenuity Pathway Analysis suite (IPA; www.
ingen uity.com). The upstream regulator analysis tool of IPA 
was used to assess the activity of upstream regulators as re-
ported.46 Briefly, the gene expression levels of all known target 
genes of an upstream regulator of interest were analyzed to-
gether. A Z-score less than −2 indicates a significantly reduced 
transcriptional activity, while a Z-score greater than 2 indicates 
significant activation based on the direction of gene expression 
changes of target genes as reported in translational studies.23
2.14 | Immunohistochemistry on 
brain tissue
The left brain hemisphere was immersion-fixated overnight at 
4°C in 4% paraformaldehyde in 0.1 M PBS, and subsequently 
stored at 4°C in 0.1 M PBS with 0.01% sodium azide. Coronal 
frozen brain sections (−60°C) were cut in 8 series of 30-μm-
thick sections that were used for diaminobenzidine-nickel 
(DAB-Ni) immunohistochemical (IHC) staining purposes. 
IHC was performed using standard free-floating labeling pro-
cedures, using the protocol described in other studies.34,44,47
Brain sections were stained for doublecortin (DCX) as 
marker for immature neurons (neurogenesis) using poly-
clonal goat anti-doublecortin (1:8000; sc-8066 Santa Cruz 
Biotechnology Inc, Santa Cruz, CA, USA). Glucose trans-
porter 1 (GLUT-1) stainings were used to quantify the amount 
of glucose transporters on brain blood vessels (indication for 
blood vessel wall integrity) with GLUT-1 polyclonal rabbit an-
ti-GLUT1 (1:80 000; Chemicon International Inc, Temecula, 
CA, USA). To asses activated microglia (measure for neu-
roinflammation) ionized calcium-binding adapter molecule 1 
(IBA-1) was stained with polyclonal goat anti-IBA1 (1:8000, 
Abcam, Cambridge, United Kingdom). Secondary antibodies 
donkey anti-goat biotin (1:1500; Jackson ImmunoResearch, 
West Grove, PA, USA) and donkey anti-rabbit biotin (1:1500; 
Jackson ImmunoResearch) were used.
DCX-positive cells were quantified in the hippocampus 
(−1.97  mm posterior to bregma) in three successive sec-
tions per mouse. Stained brain regions were counted at 40x 
magnification by two independent observers using a Zeiss 
Axioscop microscope equipped with hardware and soft-
ware of MBF Bioscience (Williston, VT, USA). GLUT-1 
and IBA-1 positive (+) DAB-Ni immunohistochemistry was 
scored using ImageJ, in sections photographed with an Axio 
Imager A2 (Zeiss Germany). Measurements of IBA-1 and 
GLUT-1 density were defined as the area covered with either 
(a) relative IBA-1+ or GLUT-1+ staining, or (b) IBA-1+ or 
GLUT-1+ staining per mm2, all in the cortex, thalamus and 
hippocampus (bregma −1.97 mm). In addition, the intensity 
of the GLUT-1 staining was calculated by subtracting the 
mean particle intensity from 255.48 Intensity was quantified 
using ImageJ, in the same regions mentioned above.
2.15 | Statistics
The upstream regulators were analyzed using the upstream 
regulator analysis tool of IPA. All other data were analyzed 
using IBM SPSS for Windows 25.0 software (SPSS Inc, 
Chicago, IL, USA), and are expressed as mean ± SEM.
Parameters that were measured at multiple separate time 
points (ie, body weight, caloric intake, and the acquisition of the 
MWM) were analyzed using repeated measures ANOVA with 
Bonferroni correction for multiple comparisons. The post hoc 
Dunnett's multiple comparison two-sided t test was used to com-
pare treatment groups to the HFD control group. In addition, 
significant effects were also compared to the chow group using 
the same Dunnett's post hoc test. These results are described 
in Table S2. To compare treatment groups to the HFD control 
group and the chow control group, the post hoc Dunnett's mul-
tiple comparison two-sided t test was used. When a significant 
interaction between diet and time was present, the data were 
split for the concerning factor and analyzed again with repeated 
measures ANOVA. All other data (behavioral tests, imaging, 
biochemistry) were analyzed using multivariate ANOVA with 
Bonferroni correction for multiple comparisons (normally dis-
tributed) followed by Dunnett's multiple comparison two-sided 
t test, or Kruskal–Wallis test (not normally distributed data) fol-
lowed by a post hoc Mann-Whitney U test to compare groups 
to the HFD and chow group. Statistical outliers were removed 
from the dataset. The number of mice that was considered an 
outlier per test is described in Table S3.
3 |  RESULTS
3.1 | PA attenuates HFD-induced obesity 
independent of food intake
During the 16-week run-in period, HFD-treated mice gained 
significantly more weight than the reference mice on chow 
(P  <  .001; see Figure  1B). After 12  weeks of treatment 
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these weight gain differences persisted with HFD-fed mice 
being significantly heavier than chow-fed mice (P < .001). 
Body weight attenuating effects were not observed for CA, 
whereas PA markedly attenuated HFD-induced body weight 
gain (P < .05 vs HFD). Average caloric intake was slightly 
lower in HFD compared to chow (P < .05, Table 1). Caloric 
intake between HFD, CA and PA did not differ.
3.2 | PA attenuated metabolic risk 
factors and systolic blood pressure
We next examined the effects of the treatments on metabolic 
risk factors (Table  1). Plasma cholesterol and triglyceride 
concentrations were increased by HFD (P  <  .01), and this 
was not affected by CA or PA. Glucose levels were compa-
rable in all groups (Table 1). Insulin levels were significantly 
increased by HFD (P < .01). CA did not affect plasma insu-
lin, while PA reduced the HFD-induced increase in plasma 
insulin levels (P < .05).
Obesity-associated hypertension was assessed by measur-
ing SBP before and after treatment. HFD-fed mice had a sig-
nificantly higher SBP than chow-fed mice before the start of 
CA and PA treatment (P < .001) and this difference persisted 
until the end of the experiment (P < .001). CA had no signif-
icant effect on SBP, whereas PA lowered the HFD-induced 
increase in SBP (P < .01; Table 1).
Plasma concentrations of SAA, an inflammatory marker 
produced by inflamed adipose tissue and liver,49 were low 
on chow, and significantly increased by HFD (P  <  .001). 
SAA was unchanged by CA treatment, and PA treatment 
tended to reduce the HFD-induced increase in SAA levels 
(P = .056).
3.3 | PA treatment reduces HFD-
induced liver steatosis, inflammation and 
collagen content
We next studied the liver, which is the first organ SCFAs pass 
after absorption from the intestine. Liver weight increased on 
HFD (P < .001, Figure 2A) and was not affected by CA or 
PA. HE-stained liver cross-sections were analyzed for histo-
pathological features of NAFLD (Figure 2B). Macrovesicular 
steatosis (Figure 2C) was hardly present in the chow group, 
whereas the HFD-fed mice developed pronounced macrove-
sicular steatosis (P < .001). CA treatment did not affect mac-
rovesicular steatosis. In contrast, PA treatment significantly 
reduced HFD-induced macrovesicular steatosis (P  <  .05). 
Microvesicular steatosis was also increased in HFD-fed ani-
mals (Figure  2D) (P  <  .001), with no effect of CA and a 
trend reduction by PA (P = .08). The cross-sectional area that 
was covered with abnormally enlarged hepatocytes (hepato-
cellular hypertrophy; Figure 2E) was strongly increased by 
HFD (P < .05) and this HFD-induced increase was signifi-
cantly reduced by PA only (P <  .05). Inflammatory aggre-
gates were practically absent on chow (Figure 2F), whereas 
HFD livers showed a high number of inflammatory aggre-
gates (P < .001). CA did not significantly affect the number 
of inflammatory aggregates. However, PA reduced the HFD-
induced number of inflammatory aggregates (P < .01).
Hepatic collagen content was determined as a measure of 
fibrosis (Figure 2G). The hepatic collagen content was markedly 
increased by HFD (P < .01). Liver fibrosis was not affected by 
CA, while PA decreased hepatic collagen content (P < .01).
Histopathological analyses were supplemented by mea-
surement of liver lipids, β-hydroxybutyrate and glycogen in 
liver homogenates. Liver lipid analysis of cholesteryl esters 
Chow HFD CA PA
Body weight 
(g)
35.61 ± 0.83 48.04 ± 1.62*** 46.35 ± 1.54 43.17 ± 1.13& 
Average caloric 
intakea (kcal/
day/mouse)
13.77 ± 0.68 11.52 ± 0.67* 11.96 ± 0.45 11.68 ± 0.24
Cholesterol 
(mM)
7.36 ± 0.46 34.78 ± 2.95*** 32.53 ± 2.64 30.94 ± 2.16
Triglycerides 
(mmol/L)
1.71 ± 0.16 5.70 ± 0.80*** 5.38 ± 0.89 4.52 ± 0.94
Glucose 
(mmol/L)
6.89 ± 0.33 6.65 ± 0.34 6.87 ± 0.21 7.19 ± 0.14
Insulin(ng/mL) 2.25 ± 0.47 4.68 ± 0.63** 4.07 ± 0.47 3.23 ± 0.31& 
SBP (mm Hg) 107.33 ± 2.15 126.79 ± 1.43*** 122.27 ± 2.81 116.93 ± 1.53& 
SAA (ug/mL) 11.30 ± 0.67 26.94 ± 2.14*** 26.24 ± 1.67 21.38 ± 1.45
Note: Data are presented as Mean ± SEM.
aAverage food intake during the 12-week treatment period. 
*P < .05; **P < .01; ***P < .001 compared to control. &P < .05 compared to HFD. 
T A B L E  1  Metabolic parameters at the 
end of the experiment
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F I G U R E  2  Effect of 12-week treatment with CA and PA on the liver. A, Liver weight, (B) representative images of hematoxylin-eosin 
stained liver sections, (C) macrovesicular steatosis, (D) microvesicular steatosis, (E) hepatocellular hypertrophy and (F) hepatic inflammation. 
Liver homogenates were analyzed for G) collagen content, (H) cholesteryl esters (CE), triglycerides (TG) and free cholesterol (FC), (I) ketone 
body β-hydroxybutyrate as marker for the rate of β-oxidation and (J) glycogen. HFD: high-fat diet; PA: propionic acid; CA: caproic acid. Data are 
presented as mean ± SEM, *P < .05 or **P < .01 or ***P < .001 compared to HFD
   | 9TENGELER ET aL.
(CE), triglycerides (TG), and free cholesterol (FC), showed 
that CE and TG increased pronouncedly on HFD (CE and TG: 
P < .001; Figure 2H). CA did not alter any of the liver lipids, 
whereas PA lowered the HFD-induced CE levels (P < .05). 
The concentrations of β-hydroxybutyrate, a ketone body that 
is formed during beta-oxidation of lipids, were not affected 
by CA and PA (Figure 2I). Since hepatic steatosis and insulin 
resistance are associated with impairment of glycogen syn-
thesis,50 we quantified hepatic glycogen levels (Figure  3J). 
HFD reduced glycogen levels relative to chow (P  <  .001). 
The HFD-induced reduction in glycogen levels was partly 
prevented by CA (P < .01) and PA treatment (P < .05).
Collectively, these data show that CA had no effect on 
liver pathology, whereas the attenuating effects of PA on obe-
sity and metabolic risk factors were paralleled by pronounced 
reductions in NASH and fibrosis.
3.4 | PA reduced subcutaneous fat mass and 
increased the frequency of small adipocytes
Next, we determined whether the observed reduction in body 
weight with PA was accompanied by an effect on adiposity, 
adipocyte morphology, and inflammation in different fat depots 
(Figure 3). sWAT, gWAT, and mWAT weight were increased by 
HFD treatment (all P < .001 vs chow, Figure 3A-C). CA did not 
affect the mass of these depots, while PA significantly reduced 
WAT mass relative to HFD (P < .05) and non-significantly low-
ered mWAT mass relative to HFD (P = .08).
Relative to chow, HFD feeding resulted in a shift toward an 
increased frequency of hypertrophic adipocytes in all three de-
pots (% of adipocytes >8000 µm2: P < .001 in sWAT; P < .01 in 
gWAT and P < .001 in mWAT; Figure 3D-F) with a concomi-
tant reduction in small adipocytes (% of adipocytes <2000 µm2: 
P < .001 in sWAT; P < .05 in mWAT and P < .01 in eWAT; 
Figure 3D-F). Only PA was able to affect these HFD-induced 
changes, with an increased frequency of small adipocytes in 
sWAT (2000-4000  µm2, P  <  .05) and reduced frequency of 
hypertrophic adipocytes in mWAT (>8000  µm2; P  <  .05). 
WAT inflammation, as quantified by the number of crown-like 
structures (CLS) was practically absent on chow (Figure 3G-I). 
HFD-feeding increased the number of CLS relative to chow in 
gWAT (P < .001) and mWAT (P < .05). CA and PA treatment 
did not affect CLS counts in these depots relative to HFD.
Taken together, PA had a modest effect on adiposity 
in sWAT but did not reduce WAT inflammation in sWAT, 
gWAT or mWAT.
3.5 | CA and PA do not affect behavior or 
spatial memory
Motor coordination was studied with the Rotarod. HFD-fed 
mice had a lower latency to fall compared to the chow-fed 
mice before the start of the interventions (P < .001; Figure 
S1A). At the end of the experiment, HFD still had a lower 
latency to fall off the rod compared to chow mice (P < .001) 
and this was not affected by CA or PA (Figure 4A).
We did not find differences in exploration or locomo-
tion activity in the open field test before the start of the in-
terventions (Figure S1B) and at the end of the experiment 
(Figure  4B). However, PA mice spent less time in the pe-
riphery and more time in the corners of the open field than 
chow mice (P < .05; Figure 4B), whereas frequency of enter-
ing the corners did not differ between groups. This suggests 
increased anxiety in PA mice. In addition, PA mice showed 
lower walking velocity and reduced total distance moved 
than chow mice (Figure S1C,D; Table S2), although no dif-
ferences between groups were observed in home cage activity 
during the day or night as monitored in the DVC before the 
start of the interventions and at the end of the experiment 
(Figure S2A,B).
Spatial learning and memory of the mice were tested with 
the MWM test. All mice learned to find the hidden platform 
and showed a significant learning effect between day 1-2, 
day 1-3, and day 1-4 (P < .001) during the acquisition phase 
before the start of the treatments (Figure  4C). When the 
MWM was repeated after 10 weeks of treatment, we similarly 
found that mice were still able to find the hidden platform 
after 25-54  seconds with no differences between the treat-
ment groups. Next, a probe test was performed in which the 
platform of the MWM was removed. No significant effects 
between treatment groups were observed at the start of the 
intervention (Figure S1E-G) and at the end of the experiment 
in mean swimming velocity, the frequency to visit the former 
platform location, or time spent in the former platform loca-
tion (Figure 5D-F).
Collectively, these behavioral experiments show that 
CA and PA were not able to reverse the HFD-induced re-
duced motor coordination in the rotarod test. Exploration 
activity and spatial learning and memory were not affected 
by HFD-feeding and were not affected by CA and PA 
treatment.
3.6 | PA treatment reverts HFD-induced 
changes in cerebral vasoreactivity
Effects on cerebrovasculature were assessed by measure-
ment of CBF in the cortex, thalamus and hippocampus 
under normal and vasoconstrictive conditions. These two 
parameters were then used to calculate cerebral vasoreactiv-
ity a measure of the ability to respond to vasoconstrictive 
stimuli. CBF under normal and vasoconstrictive conditions 
did not differ between groups in any of the regions assessed 
(Figure 5A,B). While HFD (relative to chow) and CA (rela-
tive to HFD) had no effect on cerebral vasoreactivity, PA 
significantly improved cerebral vasoreactivity in the cortex 
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F I G U R E  3  Adipose tissue analysis of subcutaneous (sWAT), gonadal (gWAT), and mesenteric (mWAT) depots after 12 weeks of CA and 
PA treatment: (A) sWAT (B) gWAT, and (C) mWAT weight. Distribution of adipocyte sizes in (D) sWAT, (E) gWAT, and (F) mWAT. Number 
of crown-like structures (CLS) per 1000 adipocytes in (G) sWAT, (H) gWAT, and (I) mWAT. HFD: high-fat diet; PA: propionic acid; CA: caproic 
acid. Data are presented as mean ± SEM, *P < .05 or **P < .01 or ***P < .001 compared to HFD control
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and hippocampus (P <  .05 compared to HFD; Figure 5C) 
and reverted cerebral vasoreactivity to chow levels (P > .05 
compared to chow).
Immunohistochemical stainings were performed to as-
sess neurogenesis (DCX), neuroinflammation (IBA-1), and 
cerebrovascular integrity (GLUT-1). No differences between 
F I G U R E  4  Behavioral and cognitive tests. A, Latency to fall from the rotating rod. B, Cumulative duration(s) spent in corners, periphery 
and center in the open field test. C, Acquisition test of the Morris water maze (MWM) before and after treatment. The latency to find the platform 
was measured on 4 consecutive days. D, Mean swim velocity, (E) frequency of crossing the former platform location, and (F) total time spent at 
the former platform location during the probe test of the MWM. HFD: high-fat diet; PA: propionic acid; CA: caproic acid. Data are presented as 
mean ± SEM, *P < .0. Open field test: N = 14 (chow and HFD) or N = 15 (CA and PA) per group. MWM and Rotarod: N = 14 (HFD) or N = 15 
(chow, CA, PA) mice per group
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groups were observed in the number of DCX+ cells in the 
hippocampus (Figure S3A). Furthermore, no differences 
between groups were observed in the amount of IBA-1+ 
staining or relative IBA-1+ positive area in the cortex, hip-
pocampus or thalamus (Figure S3B,C). HFD-fed mice had a 
smaller relative GLUT-1+ area in the thalamus than chow-fed 
mice (P <  .05; Figure 5D). CA had no effect, whereas PA 
increased the GLUT-1+ area (P <  .05) and the number of 
GLUT-1+ particles per mm2 measures for blood vessel den-
sity, in the hippocampus (P < .05; Figure 5D,E). The number 
of GLUT-1+ particles per mm2 was even higher than in chow 
mice (P < .05). GLUT-1 intensity, reflecting the amount of 
F I G U R E  5  Cerebrovascular parameters. A, Cerebral blood flow (CBF) levels were assessed under normal conditions; and (B) under 
vasoconstrictive conditions in the cortex, hippocampus, and thalamus. C, Cerebral vasoreactivity was measured using normal and vasoconstrictive 
CBF, as a measure of ability to respond to vasoconstrictive stimuli (D) Representative images of GLUT-1 staining in Chow, HFD, CA, and PA 
mice (5 × objective, scale bar represents 500 µm). E, Quantification of the relative GLUT-1+ area, and (F) amount of GLUT-1+ particles per mm2 
in the cortex, hippocampus and thalamus. HFD: high-fat diet; PA: propionic acid; CA: caproic acid; CBF: cerebral blood flow; GLUT-1: glucose 
transporter type 1. Data are presented as mean ± SEM, *P < .05 or **P < .01 or #P < .08. CBF: N = 14 (chow and CA), N = 13 (HFD) and N = 15 
(PA). GLUT-1: N = 14 (HFD), N = 14 (chow, CA) or N = 15 (PA) mice per group
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GLUT-1 transporters, was not affected by HFD (compared 
to chow) or CA (compared to HFD). However, we observed 
a trend toward an increased GLUT-1 intensity in PA mice 
compared to HFD in the cortex (P = .056) and hippocampus 
(P =  .079). GLUT-1 intensity in PA mice was even higher 
than in chow mice in the hippocampus (P < .05; Figure S3D).
In summary, PA reduces cerebrovascular activity in the 
hippocampus and cortex to chow levels and increases the 
number of GLUT-1+ particles per mm2, reflecting vascular 
density, and GLUT-1 intensity, a marker for the amount of 
GLUT-1 transporters, in the hippocampus.51
3.7 | PA reverts HFD-induced effects in 
functional connectivity and microstructural 
gray and white matter integrity
To gain insight into functional and microstructural brain 
changes in HFD-induced obesity and the effects of CA and 
PA thereupon, mitochondrial enzyme activity analysis, rs-
fMRI, and DTI were performed.
Cerebellar mitochondrial CS enzyme activity was compa-
rable in all groups and the activity of complexes (I – IV) were 
unaffected by the treatments (Figure S4).
Functional connectivity was assessed by rs-fMRI using 
total and partial correlation analyses. Here, we observed no 
differences in functional connectivity, as analyzed with total 
correlations (Figure S5). Partial correlation highlights the 
direct connectivity between two regions. A reduction in par-
tial functional connectivity was observed between the visual 
and auditory cortex in HFD mice compared to chow mice 
(P < .001; Figure 6A,B). CA and PA had no effect on func-
tional connectivity compared to HFD. However, the func-
tional connectivity of CA and PA mice was comparable to 
chow mice (P > .05), suggesting that CA and PA were able 
to revert the HFD-induced effects in functional connectivity.
Next, DTI was used to assess gray and white matter integ-
rity in several brain regions. The FA was higher in HFD mice 
than in chow-fed mice in the somatosensory cortex (P < .05) 
and visual cortex (P < .05). No effects of CA or PA on the 
HFD-induced increase in FA levels in these brain regions 
were observed. However, FA levels of PA mice were com-
parable to chow (P  >  .05), indicating that PA reverted the 
HFD-induced effects in the somatosensory cortex and visual 
cortex. Furthermore, HFD and CA had no effects on the FA 
in the hippocampus and motor cortex, but PA-treated mice 
had a significantly lower FA in the hippocampus (P < .01) 
and motor cortex (P < .05; Figure 6C) than HFD mice. The 
FA in these regions in PA mice was comparable to chow 
(both regions P > .05).
The mean diffusivity (MD) in the hippocampus, motor 
cortex, somatosensory cortex and visual cortex were not 
affected by HFD (relative to chow), CA and PA (relative 
to HFD) (Figure  6D). MD in the optic tract was signifi-
cantly lower in HFD-fed animals than in chow-fed animals 
(P < .001, Figure 6D). CA and PA did not affect MD relative 
to HFD in any of the regions assessed. However, MD did not 
differ between PA-fed mice and chow mice in the optic tract 
(P > .05), suggesting that PA reverted the HFD-induced ef-
fects on the MD in this region.
Taken together, CA and PA were able to revert the HFD-
induced effects in functional connectivity between the visual 
and auditory cortex. PA altered microstructural gray matter 
integrity in the hippocampus and motor cortex, but this was 
not significant when compared to chow. In addition, PA re-
verted the HFD-induced effects in the somatosensory cortex, 
visual cortex and optic tract.
3.8 | PA affects genes and upstream 
regulators involved in synaptogenesis and 
inflammation
Hippocampal gene expression was studied using qRT-PCR 
and a multiplex neuroinflammation panel. Post synaptic 
density marker Psd95 mRNA levels did not differ between 
the experimental groups (Figure  7A). Also, no differences 
between chow, HFD and CA mice were observed in synap-
tophysin (Syp1) mRNA levels. A trend toward reduced ex-
pression of synaptophysin in the hippocampus was observed 
in mice that received PA (P = .055 vs HFD; Figure 7B), how-
ever, this was not significant when compared to chow.
A more extensive gene profiling analysis using a neuroin-
flammation panel followed by an upstream regulator analysis 
and an enrichment analysis across biological pathways con-
firmed this effect. There were no significant changes in pre-
dicted activation state of upstream regulators between chow 
and HFD (Figure  7C; signaling downstream of IFNG and 
STAT1 was significantly enriched in HFD but did not reach 
the cut-off value for relevant inhibition or activation). PA 
inhibited specific upstream regulators important in synapto-
genesis relative to HFD (eg, GH1, WNT3A, VEGFA, BDNF, 
EGF, JUN; see Figure 7C). PA also attenuated signaling of 
the N-methyl-D-aspartate (NMDA) receptor a post-synaptic 
glutamate receptor involved in excitatory neurotransmission, 
important for synaptic plasticity and memory function. In ad-
dition, PA inhibited inflammatory pathways downstream of 
for example, IL-1, IL-1B, IL17A, Il-33, CXCL12. The above 
findings are supported by canonical pathway analysis show-
ing significant inhibition of synaptogenesis and glutamate re-
ceptor signaling, neuroinflammation and lipopolysaccharide 
(LPS)-stimulated mitogen-activated kinase (MAPK) signal-
ing pathways by PA (all P < .05).
Altogether, we found that PA treatment showed anti-in-
flammatory effects and reduced synaptogenesis and synaptic 
plasticity signaling.
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4 |  DISCUSSION
The present study examined the potential health effects of 
PA and CA treatment on obesity-induced liver fibrosis as 
well as brain function and structure. Such effects have, to our 
knowledge, not been investigated so far and, and in case of 
CA, there are no published studies in rodent models of diet-
induced obesity, dysmetabolism, and inflammation.
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F I G U R E  6  Connectivity between brain regions and white matter integrity. A, Partial correlation matrixes of the Chow, HFD, CA, and PA 
experimental groups. The selected brain regions (dorsal hippocampus (DH), ventral hippocampus (VH), auditory cortex (AC), motor cortex (MC), 
somatosensory cortex (SSC), and visual cortex (VC) are subdivided in left hemisphere (first row) and right hemisphere (second row). A higher 
Z-score (red) indicates a stronger functional connectivity. B, Statistical analysis of functional connectivity between HFD and chow, CA and HFD, 
and PA and HFD. Minus (−) symbols in the matrix indicate whether the connectivity was decreased. Orange: P < .05). C, Differences in fractional 
anisotropy, and (D) mean diffusivity between the experimental groups in the hippocampus, motor cortex, somatosensory cortex, and visual cortex. 
Data are presented as mean ± SEM, *P < .05, **P < .01. N = 14 (HFD) or N = 15 (chow, CA, PA) mice per group
F I G U R E  7  Hippocampal synaptophysin, post-synaptic density, and upstream regulators. A, Post-synaptic density-95 and (B) Synaptophysin 
mRNA expression levels in the hippocampus. N = 14 (HFD) or N = 15 (chow, CA, PA) mice per group. C, Changes in upstream regulators are 
predicted from changes in transcription factors or key regulators with a Z-score. Z < −2 indicates a relevant inhibition (shown in green) and Z > 2 
indicates a relevant activation. Significant changes with Z < −1.96 are shown in light green. N/A indicates an insufficient number of differentially 
expressed genes to link gene effects to an upstream regulator. The p-value indicates significant enrichment of the genes downstream of a regulator. 
N = 8 per group. Data are presented as mean ± SEM
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In the present study, CA treatment showed no significant 
effects on body weight, plasma lipids, and metabolic risk fac-
tors as well as on liver steatosis. Interestingly, HFD treatment 
strongly lowered the hepatic glycogen content, and both CA 
and PA significantly prevented this reduction indicating an 
effect of both CA and PA on liver metabolism. A reduction 
in hepatic glycogen content appears to be indicative of a de-
fect in liver metabolism, impaired liver function, and hepatic 
insulin resistance as reported by others,52,53 an effect that 
has not been reported earlier in the HFD-fed Ldlr−/−.Leiden 
model of NASH. The hepatic glycogen augmenting effect of 
CA was paralleled by an insignificant reduction of lobular 
inflammation (by about 50%), whereas similar increases of 
hepatic glycogen with PA were associated with a reduction 
in liver inflammation. Because hepatic glycogen content is 
usually not determined in rodent studies of NAFLD/NASH, 
it is unclear whether the two effects are related to each other. 
It is well established that chronic tissue inflammation can 
impair insulin signaling, thereby, contributing to hepatic in-
sulin resistance. It is thus possible that the observed increase 
in hepatic glycogen, the formation of which requires insulin 
signaling, is secondary to a possible inflammation-quenching 
effect of CA.
In contrast to CA, PA treatment prevented further HFD-
induced weight gain independent of food intake. The attenu-
ating effect on body weight as well as the reduction in plasma 
insulin levels observed here, are in line with the study of Lin 
et al in which a similar dose of 2.2% w/w PA was used.21
In addition, we observed that HFD increases SBP, a find-
ing that is consistent with earlier studies.6,54 PA-treatment 
was able to reduce the HFD-induced increased SBP, which 
is in line with observations in two other mouse models55 and 
may be attributable to PA-induced endothelium-dependent 
vasodilation, as been previously reported in tail arteries.56 
Since high SBP is associated with high body weight57; and 
cognitive decline in humans,58 the observed effects of PA 
on SBP and body weight may reduce the risk for cognitive 
decline.
The attenuating effects of PA treatment on obesity and 
metabolic risk factors are associated with a reduction in he-
patic steatosis, accompanied by a reduction in hepatic CE 
content. These findings are in line with a previous study 
which showed reduced intrahepatic lipid accumulation in 
NAFLD patients (assessed by magnetic resonance imaging) 
upon increased colonic PA levels17 and with in vitro59,60 and 
in vivo18 studies which show inhibition of lipid synthesis by 
PA. An alternative explanation for the observed antisteatotic 
effects of PA could be a stimulation of β-oxidation by PA, as 
has been previously reported in a short-term mouse study.18 
However we did not observe any effect of PA on hepatic 
β-hydroxybutyrate, a marker for β-oxidation, indicating that 
this pathway is not of major importance in the current study. 
Discrepancies between our findings and those of den Besten 
et al could be due to differences in mouse strain and diet, 
lower dosage of PA used in our study (2.5% w/w), the thera-
peutic setting used here or the difference in methods used to 
measure β-oxidation.
PA also showed pronounced effects on hepatic inflam-
matory aggregates and collagen content, showing that PA 
can reduce development of NASH and liver fibrosis. To the 
best of our knowledge we are the first to comprehensively 
study the effects of PA on liver steatosis, inflammation, and 
fibrosis. Anti-inflammatory effects of PA have been reported 
previously for other organs and pathologies, such as acute 
leukemia,61 cardiovascular disease55,62 and inflammatory 
bowel disease63 although the underlying mechanisms remain 
unclear.
To assess effects of PA and CA on behavior and cognition, 
we performed behavioral and cognitive tests. We found that 
HFD-fed mice had reduced motor coordination in the rotarod 
test. CA and PA could not reverse this effect. PA mice spent 
more time in the corners of the open field test than chow mice, 
suggesting that PA mice were more anxious than chow-fed 
mice. Increased anxiety-like behavior after PA administration 
has been reported in other studies as well.64-66 Exploration 
activity and spatial learning and memory were not affected 
by HFD, CA, or PA. Other studies found cognitive deficits, 
increased motor activity, and impaired spatial memory in rats 
that were given PA.67-69 However, these rats were given PA 
via intracerebroventricular injections with a relatively high 
dosage (4 μL of 0.26 M) of PA.
We measured cerebral vasoreactivity, a measure of ability 
to respond to vasoconstrictive stimuli, to study the effects of 
PA and CA on cerebrovascular health. Overall, the cerebral 
vasoreactivity levels that we detected, are similar to those 
found in another study.34
The cerebral vasoreactivity levels in the cortex and hip-
pocampus were very low in HFD compared to chow, albeit 
not significant (cortex: P =  .089; hippocampus: P =  .100). 
HFD-induced obesity is associated with cerebrovascular re-
modeling,70,71 an active process of structural changes of the 
vessel wall.72 These structural changes to the vasculature can 
result in a decreased diameter of the blood vessels, and can 
lead to an exaggerated response to vasoconstrictive stimuli.73 
Hypertension can induce hyperperfusion of (brain) tissue, 
which is then followed by remodeling of the vasculature.73 
Moreover, hypertension and obesity are associated with rar-
efaction (a loss of capillaries and arterioles), which further 
contributes to vascular remodeling.73,74 In line with this, 
the relative GLUT-1+ area in the thalamus was decreased 
in HFD mice compared to chow. GLUT-1 is selectively ex-
pressed in the cerebral capillary endothelium, and is used as 
a marker for cerebrovascular integrity.34 This indicates that 
HFD is able to affect cerebrovascular integrity.
PA reverted HFD-induced effects on cerebrovascular ac-
tivity in the hippocampus and cortex to chow levels. This 
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adapted cerebral vasoreactivity is in line with the increased 
hippocampal GLUT-1, and may explain the effects of PA on 
cerebral hemodynamics. Together, this suggests that PA is 
able to revert HFD-induced vascular remodeling.
We revealed that PA reversed the HFD-induced effect 
mainly in different components of the visual system, that is, 
the visual cortex and the optic tract. HFD decreased func-
tional connectivity between the visual cortex and the auditory 
cortex, an effect that was reversed by CA and PA. Moreover, 
HFD mice had a higher FA in cortical regions, that is, the 
visual and somatosensory cortex, and a lower MD in the optic 
tract compared to chow mice. PA treatment reduced FA in the 
visual and somatosensory cortex, and increased MD in the 
optic tract, which could suggest that PA reversed the HFD-
induced effects back to chow or prevented further changes 
upon start of PA treatment. Recent studies by Medic et al and 
Ou et al, described positive associations between white mat-
ter integrity and increased adiposity.75,76 In addition, we re-
vealed possible negative effects of PA on synaptogenesis in 
the hippocampus. Gene expression analysis in the hippocam-
pus showed that synaptic signaling was reduced and associ-
ated with a reduction of glutamate signaling and upstream 
regulator NMDA in PA mice. Neuronal glutamate signaling 
is vital for the encoding of information, the formation and 
retrieval of memories, spatial recognition and the mainte-
nance of consciousness.77 NMDA receptors are involved in 
myelinating processes, and consistent herewith, NMDA re-
ceptor antagonists, like memantine and MK801, have shown 
a decrease in FA in the hippocampus of rats.78,79
In conclusion, we found that PA exerted pronounced 
positive effects on metabolic risk factors and attenuated the 
development of HFD-induced NASH and liver fibrosis. PA 
also decreased the systolic blood pressure and reverted ce-
rebral vasoreactivity. PA reverted HFD-induced effects in 
functional connectivity and microstructural gray and white 
matter integrity to chow levels, however PA also increased 
anxiety-like behavior and reduced regulation of synaptogen-
esis in the hippocampus. Therefore, caution should be used 
when considering PA as treatment, even though positive ef-
fects on metabolism, (cerebro) vasculature, and on both brain 
structure and function were observed.
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